 IRVINE, Calif., Oct. 11, 2021 GLOBE NEWSWIRE -- Reneo Pharmaceuticals, Inc. NASDAQ: RPHM, a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Ashley F. Hall, JD, to the position of Chief Development Officer. In this role, Ms. Hall will oversee nonclinical and clinical operations, global regulatory affairs, pharmaceutical development, and program management for all the companys development programs. 